Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Research & Development: 2022-2024

Historic Research & Development for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $227.7 million.

  • Day One Biopharmaceuticals' Research & Development fell 6.39% to $31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.0 million, marking a year-over-year decrease of 16.84%. This contributed to the annual value of $227.7 million for FY2024, which is 74.46% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Research & Development of $227.7 million as of FY2024, which was up 74.46% from $130.5 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Research & Development registered a high of $227.7 million during FY2024, and its lowest value of $85.6 million during FY2022.
  • For the 3-year period, Day One Biopharmaceuticals' Research & Development averaged around $147.9 million, with its median value being $130.5 million (2023).
  • Data for Day One Biopharmaceuticals' Research & Development shows a peak YoY skyrocketed of 74.46% (in 2024) over the last 5 years.
  • Day One Biopharmaceuticals' Research & Development (Yearly) stood at $85.6 million in 2022, then skyrocketed by 52.45% to $130.5 million in 2023, then soared by 74.46% to $227.7 million in 2024.